Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma

Journal of Neurosurgery

Volumn 121, Issue 6, 2014, Pages 1434-1445

  Agnihotri, Sameer ^a   Gugel, Isabel ^e   Remke, Marc ^a,b,c   Bornemann, Antje ^e   Pantazis, Georgios ^f   Mack, Stephen C ^a,b,c   Shih, David ^a,b,c   Singh, Sanjay K ^a   Sabha, Nesrin ^a   Taylor, Michael D ^a,b,c   Tatagiba, Marcos ^e   Zadeh, Gelareh ^b,d   Krischek, Boris ^e,g  

^a Arthur and Sonia Labatt Brain Tumour Research Centre   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

^g UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Molecular profiling; Pi3k akt inhibitors; Therapeutics; Vestibular schwannoma

Indexed keywords

DACTOLISIB; GEDATOLISIB; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; 1-(4-((4-(DIMETHYLAMINO)PIPERIDIN-1-YL)CARBONYL)PHENYL)-3-(4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL)UREA; IMIDAZOLE DERIVATIVE; MORPHOLINE DERIVATIVE; MTOR PROTEIN, HUMAN; QUINOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTOME; TRIAZINE DERIVATIVE;

ACOUSTIC NEUROMA; ARTICLE; CANCER GENETICS; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL LINE; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEUROMA; PATHOLOGY; PHYSIOLOGY; SCHWANN CELL; VESTIBULAR NERVE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MORPHOLINES; NEUROMA, ACOUSTIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; SCHWANN CELLS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTOME; TRIAZINES; VESTIBULAR NERVE;

EID: 84925225272     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2014.6.JNS131433     Document Type: Article

References (44)

1. Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO: Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res 68:5236-5245, 2008
2. Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, et al: The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. Glia 60:1721-1733, 2012
3. Ammoun S, Schmid MC, Zhou L, Ristic N, Ercolano E, Hilton DA, et al: Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival. Oncogene 31:1710-1722, 2012
4. Balasubramaniam A, Shannon P, Hodaie M, Laperriere N, Michaels H, Guha A: Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro Oncol 9:447-453, 2007
5. Blair KJ, Kiang A, Wang-Rodriguez J, Yu MA, Doherty JK, Ongkeko WM: EGF and bFGF promote invasion that is modulated by PI3/Akt kinase and Erk in vestibular schwannoma. Otol Neurotol 32:308-314, 2011
6. Bretscher A, Edwards K, Fehon RG: ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3:586-599, 2002
7. Carracedo A, Pandolfi PP: The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27:5527-5541, 2008
8. Erdim R, Helvacioglu F, Gormez S, Karabay KO, Aytekin V: Two-year follow-up of sirolimus-eluting stents versus paclitaxel-eluting stents in acute myocardial infarction. Int J Angiol 21:53-58, 2012
9. Flaiz C, Chernoff J, Ammoun S, Peterson JR, Hanemann CO: PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. Exp Neurol 218:137-144, 2009
10. Flaiz C, Utermark T, Parkinson DB, Poetsch A, Hanemann CO: Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells. Glia 56:506-515, 2008
11. Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, et al: Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 14:1617-1630, 2000
12. Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12:9-22, 2007
13. Hadfield KD, Smith MJ, Urquhart JE, Wallace AJ, Bowers NL, King AT, et al: Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene 29:6216-6221, 2010
14. Hilton DA, Ristic N, Hanemann CO: Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ. Histopathology 55:744-749, 2009
15. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, et al: NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 29:4250-4261, 2009
16. James MF, Stivison E, Beauchamp R, Han S, Li H, Wallace MR, et al: Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. Mol Cancer Res 10: 649-659, 2012
17. Lovmar L, Ahlford A, Jonsson M, Syvänen AC: Silhouette scores for assessment of SNP genotype clusters. BMC Genomics 6:35, 2005
18. Malinowska IA, Lee N, Kumar V, Thiele EA, Franz DN, Ashwal S, et al: Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis. PLoS ONE 8:e56199, 2013
19. Martin TP, Tzifa K, Kowalski C, Holder RL, Walsh R, Irving RM: Conservative versus primary surgical treatment of acoustic neuromas: a comparison of rates of facial nerve and hearing preservation. Clin Otolaryngol 33:228-235, 2008
20. Messerli SM, Tang Y, Giovannini M, Bronson R, Weissleder R, Breakefield XO: Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. Neoplasia 4:501-509, 2002
21. Mora A, Komander D, van Aalten DM, Alessi DR: PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol 15:161-170, 2004
22. Mukherjee J, Kamnasaran D, Balasubramaniam A, Radovanovic I, Zadeh G, Kiehl TR, et al: Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate). Cancer Res 69:5099-5107, 2009
23. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al: Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29:1408-1414, 2011
24. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522, 2010
25. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508, 2006
26. Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S, Kool M, et al: FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol 29:3852-3861, 2011
27. Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, et al: Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 61:6885-6891, 2001
28. Rong R, Tang X, Gutmann DH, Ye K: Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A 101:18200-18205, 2004
29. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, et al: Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:515-521, 1993
30. Sabha N, Au K, Agnihotri S, Singh S, Mangat R, Guha A, et al: Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells. PLoS ONE 7:e39412, 2012
31. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22:159-168, 2006
32. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101, 2005
33. Shaw RJ, Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424-430, 2006
34. Stemmer-Rachamimov AO, Xu L, Gonzalez-Agosti C, Burwick JA, Pinney D, Beauchamp R, et al: Universal absence of merlin, but not other ERM family members, in schwannomas. Am J Pathol 151:1649-1654, 1997
35. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, et al: Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425-437, 2012
36. Torres-Martin M, Lassaletta L, San-Roman-Montero J, De Campos JM, Isla A, Gavilan J, et al: Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/ MET signaling pathway and androgen receptor deregulation. Int J Oncol 42:848-862, 2013
37. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, et al: A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791-800, 1993
38. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, et al: Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 70:535-602, 2001
39. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110, 2010
40. Wilkerson MD, Hayes DN: ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26:1572-1573, 2010
41. Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, et al: Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20:143-157, 2011
42. Wong KK, Engelman JA, Cantley LC: Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20:87-90, 2010
43. Xiao GH, Beeser A, Chernoff J, Testa JR: p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem 277:883-886, 2002
44. Zeng Z, Sarbassov DD, Samudio IJ, Yee KW, Munsell MF, Jackson CE, et al: Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109:3509-3512, 2007